TOP 20

Top 20 Immunology Companies of 2026

Shots: AbbVie led the global immunology market with $30.4B in immunology revenue in 2025, followed by Sanofi ($19.08B) and Johnson & Johnson ($15.72B). Continued demand for biologics and targeted therapies across autoimmune and inflammatory diseases supported strong commercial performance among leading companies. The global immunology market, valued at $108.4B in 2024, is projected to…

1 day ago

Insights+: An Analysis of the Growth of Biopharma Companies in the Last 20 Years (2006-2025)

Shots: PharmaShots' latest report chronicles the transformation of the global biopharma industry from 2006–2025, highlighting how innovation, strategic M&A, AI adoption, and evolving commercialization strategies have reshaped the competitive landscape while companies navigated patent cliffs, pricing pressures, and shifting market dynamics. The report tracks the rise and fall of leading biopharma companies over two decades driven by…

July 10, 2026

Top 20 Vaccines of 2026

Shots: The global vaccine market, valued at $72.8B in 2025 and projected to reach $115.8B by 2033, continues to benefit from expanding immunization coverage, growing awareness of infectious disease prevention, and innovation across RSV, pneumococcal, HPV, and mRNA vaccines. Pfizer’s Prevnar Family led the market with $6.49B in revenue, followed by Merck’s Gardasil/Gardasil 9 ($5.23B)…

June 26, 2026

Top 20 Nutraceutical Companies of 2026

Shots: The global nutraceutical market is advancing through preventive healthcare, personalized nutrition, probiotics, sports nutrition, and healthy ageing solutions. In 2025, Nestlé led the industry with $18.1B in nutraceutical revenue, followed by Danone ($10.91B) and Abbott Nutrition ($8.45B), reflecting strong demand for science-backed wellness products Valued at $636.2B in 2025, the global nutraceutical market is…

June 12, 2026

Top 20 Diagnostics Companies of 2026

Shots: The global diagnostics market is rapidly evolving through AI-powered imaging, molecular testing, precision medicine, and digital pathology solutions. In 2025, Siemens Healthineers led the industry with $20.54B in diagnostics revenue, followed by Roche at $17.52B and GE HealthCare at $17.49B, reflecting the growing adoption of advanced imaging, lab automation, and AI-driven diagnostics across global…

May 29, 2026

Top 20 Medical Device Companies of 2026

Top 20 Medical Device Companies of 2026 Shots: The global medical devices market is entering a new era of transformation, powered by AI-driven diagnostics, robotic surgery, cardiovascular breakthroughs, and minimally invasive innovation. Valued at $572.31B in 2025, the market is racing toward the $1T milestone by 2034. In FY2025, Medtronic dominated with $35.48B in revenue,…

May 15, 2026

PharmaShots Awards 2026: Celebrating the Titans Transforming the Future of Global Healthcare

Shots: PharmaShots Awards 2026 celebrates the industry’s most influential innovators across biopharma, MedTech, diagnostics, generics, nutraceuticals, animal health, digital health, and AI-driven drug discovery spotlighting organizations redefining the future of global healthcare. From Eli Lilly, Pfizer, and AbbVie to Medtronic, Roche, Siemens Healthineers, and XtalPi, this year’s awardees exemplify scientific excellence, breakthrough innovation, and a relentless commitment to…

May 2, 2026

Top 20 Biopharma Deal Terminations of 2025

Shots: Biopharma dealmaking in 2025 continued to face significant headwinds, with collaborations frequently collapsing due to strategic reprioritization, fierce competitive pressures, unfavorable clinical readouts, and failure to meet key closing conditions highlighting the inherent uncertainty and capital risk embedded in innovation-driven partnerships The year underscored a clear dominance of R&D-focused collaborations and licensing agreements,…

April 24, 2026

Top 20 Biopharma Companies of 2026

Shots: The biopharma industry is a multi-hundred-billion-dollar market, with a projected compound annual growth rate (CAGR) of 8.6%, the global biopharma market is expected to reach $1.41T by 2034. Eli Lilly and Co. ranked first with $65.17B, followed by Pfizer ($61.19B) and AbbVie ($61.16B), reflecting strong market concentration among large-cap innovators with diversified, high-value portfolios …

April 10, 2026

Top 20 Healthcare IPOs of 2025

Shots: The Healthcare IPOs in 2025 underscore sustained investor confidence across biotech, medtech, digital health, and AI-enabled healthcare companies, signaling robust capital deployment into next-generation therapies, advanced diagnostics, and evolving healthcare delivery models worldwide. IPO activity was dominated by high-value raises, with Medline Industries ($7.2B) leading by a wide margin, followed by Caris Life Sciences…

March 27, 2026